Curtin N - Search Results

1

Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Zanjirband M, et al. Among authors: curtin n. Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523. Oncotarget. 2024. PMID: 38386812 Free PMC article. No abstract available.

2

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.

Zanjirband M, Curtin N, Edmondson RJ, Lunec J. Zanjirband M, et al. Among authors: curtin n. Oncotarget. 2017 Jul 15;8(41):69779-69796. doi: 10.18632/oncotarget.19266. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050241 Free PMC article.

3

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.

Middleton FK, Patterson MJ, Elstob CJ, Fordham S, Herriott A, Wade MA, McCormick A, Edmondson R, May FE, Allan JM, Pollard JR, Curtin NJ. Middleton FK, et al. Oncotarget. 2015 Oct 20;6(32):32396-409. doi: 10.18632/oncotarget.6136. Oncotarget. 2015. PMID: 26486089 Free PMC article.

4

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E. Herriott A, et al. Among authors: curtin nj. Oncotarget. 2015 Dec 22;6(41):43978-91. doi: 10.18632/oncotarget.6287. Oncotarget. 2015. PMID: 26539646 Free PMC article.

5

Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

McCormick A, Donoghue P, Dixon M, O'Sullivan R, O'Donnell RL, Murray J, Kaufmann A, Curtin NJ, Edmondson RJ. McCormick A, et al. Clin Cancer Res. 2017 Apr 15;23(8):2050-2060. doi: 10.1158/1078-0432.CCR-16-0564. Epub 2016 Oct 4. Clin Cancer Res. 2017. PMID: 27702817 Free PMC article.

6

Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity.

O'Donnell RL, Kaufmann A, Woodhouse L, McCormick A, Cross PA, Edmondson RJ, Curtin NJ. O'Donnell RL, et al. Int J Gynecol Cancer. 2016 Jul;26(6):1004-11. doi: 10.1097/IGC.0000000000000745. Int J Gynecol Cancer. 2016. PMID: 27327149

7

Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor.

Franklin M, Gentles L, Matheson E, Bown N, Cross P, Ralte A, Gilkes-Immeson C, Bradbury A, Zanjirband M, Lunec J, Drew Y, O'Donnell R, Curtin NJ. Franklin M, et al. Among authors: curtin nj. Cancer Med. 2018 Sep;7(9):4744-4754. doi: 10.1002/cam4.1724. Epub 2018 Aug 14. Cancer Med. 2018. PMID: 30109783 Free PMC article.

8

The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis.

O Donnell RL, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufman A, Soohoo S, Elattar A, Curtin NJ, Edmondson RJ. O Donnell RL, et al. PLoS One. 2014 Mar 6;9(6):e90604. doi: 10.1371/journal.pone.0090604. eCollection 2014. PLoS One. 2014. PMID: 24603616 Free PMC article.

9

Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.

Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ. Kotsopoulos IC, et al. Int J Gynecol Cancer. 2016 May;26(4):763-9. doi: 10.1097/IGC.0000000000000654. Int J Gynecol Cancer. 2016. PMID: 26905326 Review.

10

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

Hardcastle IR, Ahmed SU, Atkins H, Calvert AH, Curtin NJ, Farnie G, Golding BT, Griffin RJ, Guyenne S, Hutton C, Källblad P, Kemp SJ, Kitching MS, Newell DR, Norbedo S, Northen JS, Reid RJ, Saravanan K, Willems HM, Lunec J. Hardcastle IR, et al. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1515-20. doi: 10.1016/j.bmcl.2004.12.061. Bioorg Med Chem Lett. 2005. PMID: 15713419

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

286 results

Search Page